

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet	1	of	3
-------	---	----	---

**Complete if Known**

Application Number	10/756,802
Filing Date	January 13, 2004
First Named Inventor	BAMDAD, Cynthia C.
Art Unit	1634
Examiner Name	FORMAN, BETTY J
Attorney Docket Number	M1015.70070US01

## U. S. PATENT DOCUMENTS

[illegible]

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear
		Country Code <sup>2</sup> Number <sup>4</sup> Kind Code <sup>5</sup> (if known)	MM-DD-YYYY		
		WO 00/33079	00-00-2000	Nanosphere LLC	Whole Document
		WO 00/43791	07-27-2000	Mitsubishi Electric Industrial Corporation	Whole Document
/BF/		WO 99/45149	09-10-1999	Lifespan Biosciences, Inc.	Whole Document
		JP 10-607367A	07-21-1998	Lynx Therapeutics, Inc.	Whole Document

Examiner Signature	/Betty Forman/	Date Considered	03/15/2010
-----------------------	----------------	--------------------	------------

EXAMINER. Initial if reference considered, whether or not citation is in conformance with WPO 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinde Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or WPO 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WPO Standard ST-16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language. Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 USC 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

**Complete if Known**

<b>Application Number</b>	10/756,802
<b>Filing Date</b>	January 13, 2004
<b>First Named Inventor</b>	BAMDAD, Cynthia C.
<b>Art Unit</b>	1634
<b>Examiner Name</b>	FORMAN, BETTY J
<b>Attorney Docket Number</b>	M1015.70070US01

Sheet 2 of 3

**NON PATENT LITERATURE DOCUMENTS**

ABSTRACT ONLY

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
/C1	C1	Wiebe, Li, "Drug Delivery Systems—Fifth US-Japan Symposium. 12-17 December 1999, Lahaina, Hawaii," <i>Drugs</i> , 2000 March; 3(3):271-4.	
/BF/	C2	Sachdeva, MS, "Drug targeting systems for cancer chemotherapy," <i>Expert Opin Investig Drugs</i> , 1998 Nov; 7 (11):1649-64.	
	C3	Demers, LM, et al., "A fluorescence-based method for determining the surface coverage and hybridization efficiency of thiol-capped oligonucleotides bound to gold thin films and nanoparticles," <i>Anal Chem</i> , 2000 Nov 15; 72(22):5535-41.	
	C4	Taton, TA, et al., "Scanometric DNA array detection with nanoparticle probes," <i>Science</i> , 2000 Sep 8; 289 (5485):1757-60.	
	C5	Lin, L, et al., "Study on colloidal Au-enhanced DNA sensing by quartz crystal microbalance," <i>Biochem Biophys Res Commun</i> , 2000 Aug 11; 274(3):817-20.	
	C6	Barratt, GM, "Therapeutic applications of colloidal drug carriers," <i>Pharm Sci Technol Today</i> , 2000 May; 3 (5):163-171.	
	C7	Letsinger, RL, et al., "Use of a steroid cyclic disulfide anchor in constructing gold nanoparticle-oligonucleotide conjugates," <i>Bioconjug Chem</i> , 2000 Mar-Apr; 11(2):289-91.	
	C8	Tondelli, L, et al., "Specifically designed polymeric nanospheres increase cellular uptake of unmodified antisense ODNs," <i>Nucleosides &amp; Nucleotides</i> , 1999 Jun-July; 18(6-7):1677-9.	
	C9	Zimmer, A, "Antisense oligonucleotide delivery with polyhexylcyanoacrylate nanoparticles as carriers," <i>Methods</i> , 1999 Jul; 18(3):266-95, 322.	
	C10	Aynie, I, et al., "Sponglike alginate nanoparticles as a new potential system for the delivery of antisense oligonucleotides," <i>Antisense Nucleic Acid Drug Dev</i> , 1999 Jun; 9(3):301-12.	

<b>Examiner Signature</b>	/Betty Forman/	<b>Date Considered</b>	03/15/2010
---------------------------	----------------	------------------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

**Complete if Known**

<b>Application Number</b>	10/756,802
<b>Filing Date</b>	January 13, 2004
<b>First Named Inventor</b>	BAMDAD, Cynthia C.
<b>Art Unit</b>	1634
<b>Examiner Name</b>	FORMAN, BETTY J
<b>Attorney Docket Number</b>	M1015.7007OUS01

Sheet 3 of 3

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
/BF/	C11	Maier et al., "Quantitation of phosphorothioate oligonucleotides in human blood plasma using a nanoparticle-based method for solid-phase extraction," Anal Chem., 1998 Jun 1; 70(11):2197-204	
	C12	Fritz, H., et al., "Cationic Polystyrene Nanoparticles: Preparation and Characterization of a Model Drug Carrier System for Antisense Oligonucleotides," J Colloid Interface Sci., 1997 Nov 15; 195(2): 272-88.	
	C13	Zobel, HP, et al., "Cationic polyhexylcyanoacrylate nanoparticles as carriers for antisense oligonucleotides," Antisense Nucleic Acid Drug Dev., 1997 Oct; 7(5):483-93.	
	C14	Elghariani, R., et al., "Selective colorimetric detection of polynucleotides based on the distance-dependent optical properties of gold nanoparticles," Science, 1997 Aug 22; 277(5329):1078-81.	
	C15	Schwab, G. et al., "Antisense oligonucleotides adsorbed to polyalkylcyanoacrylate nanoparticles specifically inhibit mutated H-ras-mediated cell proliferation and tumorigenicity in nude mice," Proc Natl Acad Sci USA, 1994 Oct 25; 91(22):10460-4.	
	C16	Battersby, BJ, et al., "Toward Larger Chemical Libraries: Encoding with Fluorescent Colloids in Combinatorial Chemistry," J. Am. Chem. Soc., 2000; 122:2138-2139.	
	C17	Coester, C., et al., "Preparation of avidin-labelled gelatin nanoparticles as carriers for biotinylated peptide nucleic acid (PNA)," Int. J. Pharm., 2000 March; 196: 147-149.	
	C18	Shali, et al., "Atomic force microscopy of oriented linear DNA molecules labeled with 5nm gold spheres," Nucleic Acids Research, 1993; 21(1):99-103.	

Examiner  
Signature

/Betty Forman/

Date

Considered

03/15/2010

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.